The role of androgens in cardiovascular disease is uncertain. We aimed to determine the vascular effects of androgen suppression in men with prostate cancer. Arterial stiffness (or ‘compliance’) was measured in 16 men (71±9 years, mean±S.D.) prior to, and 3 months after, complete androgen suppression with gonadotrophin-releasing hormone analogues as treatment for prostate cancer. Fifteen control men (70±7 years) also had arterial stiffness studies at baseline and 3 months later. Two measures of arterial stiffness were employed: systemic arterial compliance (SAC) was measured by simultaneous recording of aortic flow and carotid artery pressure (‘area method’), and pulse wave velocities (PWVs) were recorded with the ‘Complior’ system. The 16 cases underwent glucose-tolerance and fasting-lipids tests on both visits. After 3 months of testosterone suppression, there was a significant fall in SAC, which was not seen in the controls [mean change±S.E.M., -0.26±0.09a.c.u. (arbitrary compliance unit) in the cases versus +0.06±0.11 in the controls; P = 0.03). Central, but not peripheral, PWVs tended to increase in the cases (mean change±S.E.M. for aorto-femoral PWV, +0.5±0.4m/s for cases versus -0.3±0.3m/s for controls; P = 0.08). After testosterone suppression, fasting insulin levels increased from 6.89±4.84m-units/l to 11.34±8.16m-units/l (mean±S.D.), total cholesterol increased from 5.32±0.77mmol/l to 5.71±0.82mmol/l and high-density lipoprotein cholesterol increased from 1.05±0.24mmol/l to 1.26±0.36mmol/l; P<0.005 for all. No significant change occurred in body-mass index, serum glucose, low-density lipoprotein cholesterol or triacylglycerol (triglyceride) levels. Our results indicate that loss of androgens in men leads to an increase in aortic stiffness and serum insulin levels, and may therefore adversely affect cardiovascular risk.
Skip Nav Destination
Article navigation
Research Article|
January 17 2003
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
Frances DOCKERY;
*Section of Geriatric Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, London W12 0NN, U.K.
Correspondence: Dr Frances Dockery (e-mail [email protected]).
Search for other works by this author on:
Christopher J. BULPITT;
Christopher J. BULPITT
*Section of Geriatric Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, London W12 0NN, U.K.
Search for other works by this author on:
Sanjiv AGARWAL;
Sanjiv AGARWAL
†Department of Urology, Hammersmith Hospital, London W12 0NN, U.K.
Search for other works by this author on:
Mandy DONALDSON;
Mandy DONALDSON
‡Department of Clinical Chemistry, Hammersmith Hospital, London W12 0NN, U.K.
Search for other works by this author on:
Chakravarthi RAJKUMAR
Chakravarthi RAJKUMAR
*Section of Geriatric Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, London W12 0NN, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
July 29 2002
Revision Received:
October 14 2002
Accepted:
November 26 2002
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society and the Medical Research Society © 2003
2003
Clin Sci (Lond) (2003) 104 (2): 195–201.
Article history
Received:
July 29 2002
Revision Received:
October 14 2002
Accepted:
November 26 2002
Citation
Frances DOCKERY, Christopher J. BULPITT, Sanjiv AGARWAL, Mandy DONALDSON, Chakravarthi RAJKUMAR; Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 1 February 2003; 104 (2): 195–201. doi: https://doi.org/10.1042/cs1040195
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |